ARVINAS INC

NASDAQ: ARVN (Arvinas, Inc.)

最近更新时间: 12 Dec, 3:29AM

12.57

-0.41 (-3.16%)

前收盘价格 12.98
收盘价格 12.99
成交量 1,131,983
平均成交量 (3个月) 2,423,239
市值 922,859,136
价格/销量 (P/S) 2.83
股市价格/股市净资产 (P/B) 1.38
52周波幅
5.90 (-53%) — 21.00 (67%)
利润日期 5 Nov 2025
营业毛利率 -10.92%
营业利益率 (TTM) 37.82%
稀释每股收益 (EPS TTM) -0.660
季度收入增长率 (YOY) 646.20%
总债务/股东权益 (D/E MRQ) 1.59%
流动比率 (MRQ) 4.58
营业现金流 (OCF TTM) -250.70 M
杠杆自由现金流 (LFCF TTM) -2.69 M
资产报酬率 (ROA TTM) -5.39%
股东权益报酬率 (ROE TTM) -7.34%

市场趋势

短期 中期
行业 Biotechnology (US) 看涨 混合的
Biotechnology (全球的) 看涨 混合的
股票 Arvinas, Inc. 看跌 看跌

AIStockmoo 评分

1.5
分析师共识 -0.5
内部交易活动 NA
价格波动 -2.0
技术平均移动指标 5.0
技术振荡指标 3.5
平均 1.50

相关股票

股票 市值 DY P/E(TTM) P/B
ARVN 923 M - - 1.38
MRNA 13 B - - 1.31
CELC 5 B - - 40.01
DNLI 3 B - - 2.86
ADPT 3 B - - 12.47
MESO 2 B - - 4.19

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

部门 Healthcare
行业 Biotechnology
投资方式 Small Value
内部持股比例 6.89%
机构持股比例 90.98%

所有权

姓名 日期 持有股份
New Leaf Venture Partners, L.L.C. 30 Sep 2025 1,585,721
52周波幅
5.90 (-53%) — 21.00 (67%)
目标价格波幅
6.00 (-52%) — 18.00 (43%)
18.00 (Barclays, 43.20%) 购买
15.00 (19.33%)
6.00 (Goldman Sachs, -52.27%) 卖出
平均值 13.60 (8.19%)
总计 4 购买, 1 卖出
平均价格@调整类型 10.46
公司 日期 目标价格 调整类型 价格@调整类型
Barclays 17 Dec 2025 18.00 (43.20%) 购买 11.72
06 Nov 2025 16.00 (27.29%) 购买 10.00
Stephens & Co. 10 Nov 2025 15.00 (19.33%) 购买 11.19
Wells Fargo 06 Nov 2025 15.00 (19.33%) 购买 10.00
BTIG 30 Oct 2025 14.00 (11.38%) 购买 9.93
Goldman Sachs 15 Oct 2025 6.00 (-52.27%) 卖出 9.46

该时间范围内无数据。

日期 类型 细节
06 Dec 2025 公告 Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
26 Nov 2025 公告 Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
24 Nov 2025 公告 Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
05 Nov 2025 公告 Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
03 Nov 2025 公告 Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting
03 Nov 2025 公告 Arvinas to Participate in Upcoming Investor Conferences
29 Oct 2025 公告 Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025
24 Oct 2025 公告 Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
22 Oct 2025 公告 Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
20 Oct 2025 公告 Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
13 Oct 2025 公告 Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
05 Oct 2025 公告 Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
01 Oct 2025 公告 Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票